Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Ayscough, Steve Trevisan, Francis Collins, Eric Lander, Craig Venter

Premium

Inpharmatica has bolstered the discovery side of its hybrid bioinformatics/drug discovery business model by appointing Andrew Ayscough as director of chemistry. Ayscough was previously director of research at British Biotech Pharmaceuticals. The company has also recruited a team of seven medicinal chemists from Millennium Pharmaceuticals.


Steve Trevisan, executive vice president and a director of Gene Logic, will step down, but will continue “in an advisory capacity” until the end of the year, the company said. Trevisan joined Gene Logic in April as part of its acquisition of Therimmune Research, where he was president and CEO.


Thomson ISI has named Francis Collins, Eric Lander, and Craig Venter among its 2003 Citation Laureates — authors of the most frequently cited papers as measured by ISI’s Citation Indexing process and therefore “potential Nobel Prize winners in 2003, or after,” according to the company. The 2003 Nobel Prizes will be announced on Oct. 6.

 

Filed under

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.